Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B/2 Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (RICOLINOSTAT) in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

NCT01997840 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01997840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01997840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B/2 Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (RICOLINOSTAT) in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 1/2
Overall status
Terminated
Start date
March 1, 2014
Completion date
February 29, 2024
Enrollment
103 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma